Tobacco Dependence Treatment in Oncology: Initial Patient Clinical Characteristics and Outcomes from Roswell Park Comprehensive Cancer Center.
cancer survivors
cognitive behavioral treatment
smoking
tobacco dependence
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
31 05 2020
31 05 2020
Historique:
received:
06
04
2020
revised:
11
05
2020
accepted:
22
05
2020
entrez:
4
6
2020
pubmed:
4
6
2020
medline:
21
10
2020
Statut:
epublish
Résumé
Despite the importance of smoking cessation to cancer care treatment, historically, few cancer centers have provided treatment for tobacco dependence. To address this gap, the National Cancer Institute (NCI) launched the Cancer Center Cessation Initiative (C3i). As part of this effort, this study examined implementation outcomes in a cohort of cancer survivors (CSs) who smoked cigarettes in the first year of an ongoing process to develop and implement a robust Tobacco Treatment Service at Roswell Park Comprehensive Cancer Center. We provide a comprehensive description of the new tobacco use assessment and referral process, and of the characteristics of cancer survivors who agreed to treatment including traditional tobacco-related psychosocial and cancer treatment-related characteristics and novel characteristics such as delay discounting rates. We also examine characteristic differences among those who agreed to treatment between those who attended and those who did not attend treatment. As the new tobacco assessment was implemented, the number of referrals increased dramatically. The mean number of treatment sessions attended was 4.45 (SD = 2.98) and the six-month point prevalence intention to treat abstinence rate among those who attended was 22.7%. However, only 6.4% agreed to treatment and 4% attended at least one treatment session. A large proportion of cancer survivors who agreed to treatment were women, of older age, of lower socioeconomic status (SES), and who had high levels of depressive symptomology. The findings demonstrate that the implementation of system changes can significantly improve the identification of cancer survivors who use tobacco and are referred to tobacco use treatment. Among those who attend, treatment is effective. However, the findings also suggest that a systematic assessment of barriers to engagement is needed and that cancer survivors may benefit from additional treatment tailoring. We present plans to address these implementation challenges. Systematic electronic medical record (EMR)-sourced referral to tobacco treatment is a powerful tool for reaching cancer survivors who smoke, but more research is needed to determine how to enhance engagement and tailor treatment processes.
Identifiants
pubmed: 32486463
pii: ijerph17113907
doi: 10.3390/ijerph17113907
pmc: PMC7312979
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIH HHS
ID : P30 CA016056-41S2
Pays : United States
Références
JAMA Netw Open. 2019 Sep 4;2(9):e1912251
pubmed: 31560387
J Clin Oncol. 2016 Apr 20;34(12):1315-22
pubmed: 26811527
MMWR Surveill Summ. 2012 Jan 20;61(1):1-23
pubmed: 22258477
Cancer Epidemiol Biomarkers Prev. 2012 Aug;21(8):1244-59
pubmed: 22695735
Addict Behav. 2005 Feb;30(2):375-81
pubmed: 15621410
Health Psychol. 2019 Jan;38(1):21-28
pubmed: 30474996
J Natl Cancer Inst. 2004 Sep 1;96(17):1322-30
pubmed: 15339970
Nicotine Tob Res. 2009 Jan;11(1):77-83
pubmed: 19246444
Front Psychiatry. 2019 Mar 21;10:112
pubmed: 30949071
Nicotine Tob Res. 2013 Jan;15(1):52-8
pubmed: 22499079
Am J Prev Med. 2013 Dec;45(6):737-41
pubmed: 24237916
Addict Behav. 2014 Nov;39(11):1682-1689
pubmed: 24878037
Ann Thorac Surg. 2009 Aug;88(2):362-70; discussion 370-1
pubmed: 19632374
J Thorac Oncol. 2018 Aug;13(8):1062-1075
pubmed: 29800746
J Gerontol Nurs. 2004 Dec;30(12):13-24
pubmed: 15624692
Drug Alcohol Depend. 2008 May 1;95(1-2):169-72
pubmed: 18243583
Exp Clin Psychopharmacol. 2012 Jun;20(3):205-12
pubmed: 22182419
Cochrane Database Syst Rev. 2013 Aug 21;(8):CD006102
pubmed: 23963776
Am J Public Health. 2012 Mar;102(3):e8-16
pubmed: 22390525
Prev Med. 2016 Nov;92:135-140
pubmed: 27471021
Nicotine Tob Res. 2015 Apr;17(4):407-21
pubmed: 25762750
Cancer. 2014 May 1;120(9):1290-314
pubmed: 24343171
Nicotine Tob Res. 2001 Aug;3(3):193-202
pubmed: 11506764
Psychol Aging. 1996 Mar;11(1):79-84
pubmed: 8726373
J Natl Compr Canc Netw. 2017 Sep;15(9):1140-1163
pubmed: 28874599
Exp Clin Psychopharmacol. 2007 Apr;15(2):176-86
pubmed: 17469941
J Natl Cancer Inst. 2011 Jan 19;103(2):117-28
pubmed: 21228314
MMWR Morb Mortal Wkly Rep. 2016 Nov 11;65(44):1205-1211
pubmed: 27832052
Cancer. 1994 Oct 1;74(7 Suppl):2055-61
pubmed: 8087771
Am J Addict. 2012 May-Jun;21(3):221-32
pubmed: 22494224
BMJ. 2010 Jan 21;340:b5569
pubmed: 20093278
Eat Behav. 2006 Aug;7(3):243-51
pubmed: 16843227
J Clin Oncol. 2015 Mar 10;33(8):885-93
pubmed: 25646196
Nicotine Tob Res. 2016 May;18(5):1002-11
pubmed: 26446070
Am J Public Health. 2013 Aug;103(8):e74-82
pubmed: 23763416
Psychiatry Res. 2015 Mar 30;226(1):73-7
pubmed: 25650047
J Cancer Surviv. 2012 Sep;6(3):333-44
pubmed: 22706885
MMWR Morb Mortal Wkly Rep. 2015 Nov 13;64(44):1233-40
pubmed: 26562061
N Engl J Med. 2019 Feb 7;380(6):512-515
pubmed: 30601710
J Clin Oncol. 2005 Dec 1;23(34):8884-93
pubmed: 16314649
Cancer Epidemiol Biomarkers Prev. 2014 Jan;23(1):3-9
pubmed: 24420982
Exp Clin Psychopharmacol. 2017 Aug;25(4):273-280
pubmed: 28627925
Addict Behav. 2015 Jun;45:124-33
pubmed: 25661991
Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):1996-2005
pubmed: 21980007
Addict Behav. 2006 Jan;31(1):115-27
pubmed: 15925449
J Cancer Surviv. 2010 Dec;4(4):313-21
pubmed: 20464638
Health Psychol. 1990;9(4):466-78
pubmed: 2373070
Psychopharmacology (Berl). 1999 Oct;146(4):447-54
pubmed: 10550495
Nicotine Tob Res. 2020 Mar 16;22(3):415-422
pubmed: 30508122
Drug Alcohol Depend. 2018 Oct 1;191:165-173
pubmed: 30121475
Drug Alcohol Depend. 2017 Dec 1;181:177-185
pubmed: 29065390
JAMA Netw Open. 2019 Apr 5;2(4):e191703
pubmed: 30951159
Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2404-11
pubmed: 24319070
Cancer. 2016 Apr 15;122(8):1247-53
pubmed: 26881851
J Clin Oncol. 2012 Oct 20;30(30):3697-704
pubmed: 23008316
Oncol Nurs Forum. 2007 May;34(3):643-51
pubmed: 17573323
CNS Drugs. 2001;15(5):391-411
pubmed: 11475944
Front Psychol. 2014 Sep 17;5:1026
pubmed: 25278917
J Psychiatr Pract. 2011 Jul;17(4):270-6
pubmed: 21775828